Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib.
Hiraoka A, Hirooka M, Koizumi Y, Izumoto H, Ueki H, Kaneto M, Kitahata S, Aibiki T, Tomida H, Miyamoto Y, Yamago H, Suga Y, Iwasaki R, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Abe M, Matsuura B, Kawasaki H, Hiasa Y, Michitaka K.
Hiraoka A, et al. Among authors: kawasaki h.
Hepatol Res. 2017 May;47(6):558-565. doi: 10.1111/hepr.12780. Epub 2016 Aug 30.
Hepatol Res. 2017.
PMID: 27480045